IBD开年大戏：2023年美国克罗恩病和结肠炎大会(CCC) IBD药物研究热点梳理

编者按：

这是“消化界”为您带来的2023年第二场国际性学术盛会。自成立之时起，“消化界”秉承“服务学科建设、推动学术交流、促进学术繁荣”的宗旨，致力于中国声音的传播，展现中国学术魅力。

2023年克罗恩与结肠炎大会（Crohn’s & Colitis Congress:registered:，CCC），由美国胃肠病协会（AGA）和美国克罗恩与结肠炎基金会（Crohn’s& Colitis Foundation）共同举办。会议于2023年1月19日-21日在美国科罗拉多州丹佛市举行。CCC聚焦以患者为中心的IBD综合护理方法，会议将讨论IBD领域当前面临的挑战，并展现最前沿的研究成果。本文汇集药物研究热点12篇，按题目中的相关化学名进行分类汇总，供读者参考。

大会官方网站：

https://crohnscolitiscongress.org

维得利珠单抗篇

1. 维得利珠单抗和托法替布联合治疗难治性溃疡性结肠炎的疗效--单中心经验

摘要：P039

TI：Efficiency of dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients-single center experience

Martin Kolar，et al.

2. 维得利珠单抗对炎症性肠病患者CD8 T细胞谱系同质性和血-肠转运的影响

摘要：P041

TI：The effect of vedolizumab on CD8 T cell repertoire homogeneity and blood-gut trafficking in patients with inflammatory bowel disease

Kyle Williams,et al.

3. 维得利珠单抗、乌司奴单抗和托法替布三联疗法治疗溃疡性结肠炎

摘要：P043

TI：Vedolizumab，ustekinumab and tofacitinib as triple therapy for ulcerative colitis

Theresa Thurston，et al.

4. 维得利珠单抗和肿瘤坏死因子抑制剂治疗激素难治性显微镜结肠炎的疗效和安全性：一项系统评价和荟萃分析

摘要：P050

TI：Efficacy and safety of vedolizumab and tumor necrosis factor inhibitors in the treatment of steroid-refractory microscopic colitis: a systematic review and meta-analysis

Nabil El Hage Chehade,et al.

5. 维得利珠单抗治疗的炎症性肠病患者肠外表现为关节炎和关节痛：一项荟萃分析

摘要：P053

TI：Arthritis and arthralgia as extraintestinal manifestations in patients with inflammatory bowel disease treated with vedolizumab：a meta-analysis

Gabriele Alves dos Anjos，et al.

阿达木单抗篇

1. 与阿达木单抗相比，生物制剂初治的克罗恩病患者在接受标签维持剂量乌司奴单抗治疗的持久性更好

摘要：P091

TI：Superior persistence while on labeled maintenance dose among bio-naive patients with crohn's disease initiated on ustekinumab compared to adalimumab

Maryia Zhdanava,et al.

2. 与阿达木单抗相比，生物制剂经治的克罗恩病患者在接受标签维持剂量乌司奴单抗治疗的持久性

摘要：P093

TI：Persistence while on labeled maintenance dose among bio-experienced patients with crohn's disease initiated on ustekinumab compared to adalimumab

Maryia Zhdanava,et al.

乌司奴单抗篇

1. 维得利珠单抗、乌司奴单抗和托法替布三联疗法治疗溃疡性结肠炎

摘要：P043

TI：Vedolizumab，ustekinumab and tofacitinib as triple therapy for ulcerative colitis

Theresa Thurston，et al.

2. 抗TNF经治的克罗恩病患者循环使用不同的抗TNF和改用乌司奴单抗与药物持久性的关系

摘要：P089

TI：Association of cycling between anti-TNFs versus switching to ustekinumab with medication persistence in anti-TNF experienced patients with crohn's disease

Maryia Zhdanava,et al.

3. 与阿达木单抗相比，生物制剂初治的克罗恩病患者在接受标签维持剂量乌司奴单抗治疗的持久性更好

摘要：P091

TI：Superior persistence while on labeled maintenance dose among bio-naive patients with crohn's disease initiated on ustekinumab compared to adalimumab

Maryia Zhdanava,et al.

4. 溃疡性结肠炎患者持续应用乌司奴单抗达到维持期的真实世界研究

摘要：P092

TI：Real-world ustekinumab persistence in patients with ulcerative colitis attaining the maintenance phase

Maryia Zhdanava,et al.

5. 与阿达木单抗相比，生物制剂经治的克罗恩病患者在接受标签维持剂量乌司奴单抗治疗的持久性

摘要：P093

TI：Persistence while on labeled maintenance dose among bio-experienced patients with crohn's disease initiated on ustekinumab compared to adalimumab

Maryia Zhdanava,et al.

英夫利昔单抗篇

1. 炎症性肠病患者加速英夫利昔单抗输注安全性和耐受性不逊于标准输注方案--随机对照研究

摘要：P033

TI：Accelerated infliximab infusion safety and tolerability is non-inferior to standard infusion protocol in inflammatory bowel disease patients-a randomized controlled study

Suha Abushamma，et al.

托法替布篇

1. 中重度溃疡性结肠炎患者托法替布剂量降梯治疗的真实经验

摘要：P038

TI：Real-world experience with tofacitinib dose deescalation in patients with moderate and severe ulcerative colitis

Amy Yu，et al.

2. 维得利珠单抗和托法替布联合治疗难治性溃疡性结肠炎的疗效--单中心经验

摘要：P039

TI：Efficiency of dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients-single center experience

Martin Kolar，et al.

3. 在单个三级护理中心11例托法替布难治性溃疡性结肠炎患者应用乌帕替尼治疗

摘要：P042

TI：Use of upadacitinib in 11 tofacitinib-refractory ulcerative colotis patients at a single tertiary care center

Jake Levine，et al.

4. 维得利珠单抗、乌司奴单抗和托法替布三联疗法治疗溃疡性结肠炎

摘要：P043

TI：Vedolizumab，ustekinumab and tofacitinib as triple therapy for ulcerative colitis

Theresa Thurston，et al.

： ， 。   视频 小程序 赞 ，轻点两下取消赞 在看 ，轻点两下取消在看